Ring Therapeutics

Executive Summary

Ring Therapeutics is pioneering a novel platform using commensal anelloviruses as vectors for gene therapy and vaccine delivery, uniquely enabling repeat dosing without anti-vector immunity. This technology addresses key limitations of current AAV-based gene therapies, such as immunogenicity and inability to re-dose. The platform has potential across genetic diseases, oncology, and infectious diseases, and the company has raised $86.5M to advance its pipeline. While still in preclinical/early clinical stages, Ring's approach could broadly expand the therapeutic index and durability of gene therapies. Key upcoming catalysts include initial proof-of-concept clinical data, strategic partnerships, and potential Series C financing to support pipeline expansion.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 clinical data for lead candidate in genetic disease40% success
• Q4 2026Partnership with major pharma for oncology/infectious disease application30% success
• Q2 2026Series C funding round to advance platform60% success